Biological Immunology

Octagam Immune Globulin (Human)

Payments companies reported to CMS as associated with Octagam Immune Globulin (Human). "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$805Kassociated payments (2023-2025)

6,781clinicians with associated payments

4companies reporting

By year

2023 $158K

2024 $274K

2025 $373K

Payments reported as associated with Octagam Immune Globulin (Human), per program year, as reported to CMS.

Who makes it

Specialties most often involved

Neurology (Psychiatry & Neurology) $223K

Rheumatology $145K

Allergy & Immunology $80K

Family $39K

Physician Assistant $27K

Pediatric Allergy/Immunology $19K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Octagam Immune Globulin (Human)

These are the largest totals companies reported as associated with Octagam Immune Globulin (Human). They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Isaac Melamed	Centennial, CO		$119,163.15
Mazen Dimachkie	Houston, TX	Neurology (Psychiatry & Neurology)	$107,564.52
Rohit Aggarwal	Pittsburgh, PA	Rheumatology	$41,205.06
Michael Daines	Tucson, AZ	Pediatric Allergy/Immunology	$14,144.94
Lisa Christopher	Baltimore, MD	Rheumatology	$11,776.89
Suraj Muley	Phoenix, AZ	Neurology (Psychiatry & Neurology)	$8,387.21
Sami Khella	Philadelphia, PA	Neurology (Psychiatry & Neurology)	$7,458.50
Alvin Wells	Destin, FL	Rheumatology	$7,243.81
Christina Charles-Schoeman	Los Angeles, CA	Rheumatology	$7,036.60
Marinos Dalakas	Philadelphia, PA	Neurology (Psychiatry & Neurology)	$6,478.16

Prescribed Octagam Immune Globulin (Human)?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.